.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Levodopa remains the most effective symptomatic treatment for Parkinson disease, but clinicians have long debated whether starting it early accelerates later motor complications or changes disease progression. The LEAP delayed-start trial followed patients with early Parkinson disease who were assigned to start levodopa immediately or after a 40-week delay. Follow-up showed that starting levodopa earlier improved symptoms of bradykinesia, rigidity and tremor during active treatment, but the delayed-start design did not demonstrate a durable disease-modifying advantage attributable to earlier initiation. Later analyses also found that early initiation was not associated with more motor fluctuations at 80 weeks. The practical message is therefore reassuring: clinicians do not need to delay levodopa solely because of fear that starting treatment early will worsen the long-term course. Treatment timing should be based on symptom burden, functional impact, patient priorities and the need to maintain quality of life. The study supports a patient-centred approach to levodopa initiation rather than rigid rules about waiting until disability becomes substantial.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Levodopa remains the most effective symptomatic treatment for Parkinson disease, but clinicians have long debated whether starting it early accelerates later motor complications or changes disease progression. The LEAP delayed-start trial followed patients with early Parkinson disease who were assigned to start levodopa immediately or after a 40-week delay. Follow-up showed that starting levodopa earlier improved symptoms of bradykinesia, rigidity and tremor during active treatment, but the delayed-start design did not demonstrate a durable disease-modifying advantage attributable to earlier initiation. Later analyses also found that early initiation was not associated with more motor fluctuations at 80 weeks. The practical message is therefore reassuring: clinicians do not need to delay levodopa solely because of fear that starting treatment early will worsen the long-term course. Treatment timing should be based on symptom burden, functional impact, patient priorities and the need to maintain quality of life. The study supports a patient-centred approach to levodopa initiation rather than rigid rules about waiting until disability becomes substantial.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
